Table 1.
Selected inhibitors of glycolysis
| Target | Agent | Cancer | References |
|---|---|---|---|
| PKM2 | TLN-232/CAP-232 | Renal, melanoma | [84, 85] |
| HK2 | 2-Deoxyglucose | Prostate | [86, 87] |
| 3-Bromopyruvate | Colorectal, breast, hepatocellular | [84, 88, 89] | |
| LDHA | FX 11 | Lymphoma, pancreatic | [90] |
| Oxamate | Nasopharyngeal | [91] | |
| PDH | CPI-613 | Small cell lung, pancreatic | [92, 93] |
| PDK | Dichloroacetate | Breast | [94, 95] |
| PFKFB3 | 3PO | Bladder, tongue | [96, 97] |
| GLUT1/3 | STF-31 | Renal | [98] |
PKM2, pyruvate kinase muscle isoform 2; HK2, hexokinase 2; LDHA, lactate dehydrogenase A; PDH, pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3; GLUT1/3, glucose transporter 1/3